New Directions in the Management of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma:
Utilizing Immunotherapy to Improve Outcomes

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and is supported by an educational grant from Merck & Co.

Registration & Date of Activity

Thursday, December 15, 2022
1:00 - 1:30 PM ET

Faculty

Kirollos S. Hanna, PharmD, BCPS, BCOP
Oncology Pharmacy Manager
M Health Fairview - Maple Grove
Assistant Professor of Pharmacy
Mayo Clinic College of Medicine
Rochester, Minnesota

ACCREDITATION STATEMENTS

PHARMACY
acpePostgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-22-042-L01-P
Credits: 0.5 hour (0.05 ceu)
Estimated time to complete activity: 30 minutes

Location: From the convenience of your home or business; accessible via both PC and MAC
Fee Information:
There is no fee for this educational activity.
Type of Activity:
Knowledge
Media: Internet

TARGET AUDIENCE

This accredited activity has been designed for oncology, managed care and specialty pharmacists.

HOW TO EARN CREDIT

Participants must 1) read the learning objectives and faculty disclosures; 2) attend and participate in the live webinar; and 3) complete the posttest and evaluation form directly after the event with a maximum of within 60 days of attending the live session. To answer the questions, click on your selected choice for each answer then proceed to the next question. Your credit will automatically uploaded to CPE Monitor.

Goal

The goal of this PowerUp Recap session is to provide learners a summary of the case-based monograph titled, New Directions in the Management of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Utilizing Immunotherapy to Improve Outcomes.
(https://www.powerpak.com/course/preamble/122784, expires November 30, 2022).

The goal of the monograph is to educate oncology, managed care, and specialty pharmacists on how to optimally manage adult patients with recurrent or metastatic head and neck squamous cell carcinoma, including ensuring appropriate access to patient-specific immunotherapy treatments, developing optimal toxicity prevention and management, and providing enhanced pharmaceutical care thus leading to optimized outcomes.

During this Recap session, learners will have the opportunity to ask Dr. Kirollos Hanna questions about the use of immunotherapy to improve outcomes for patients with recurrent or metastatic head and neck squamous cell carcinoma.

LEARNING OBJECTIVES

Upon completion of this program, participants should be better able to:

  • Recognize the role for immune checkpoint inhibitors as monotherapy and in combination with chemotherapy in recurrent or metastatic HNSCC
  • Describe approaches to recognize and manage patients' immune-related adverse events in recurrent or metastatic HNSCC treatment

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5